| P50 | author | Elisa Ovidi | Q73006856 |
| | Valentina Laghezza Masci | Q87713466 |
| P2093 | author name string | A Tiezzi | |
| | S Bernardini | |
| P2860 | cites work | The pharmaceutical industry and natural products: historical status and new trends | Q58856029 |
| | Crenuladial, an antimicrobial diterpenoid from the brown alga Dilophus ligulatus | Q105113887 |
| | Biodiversity: A continuing source of novel drug leads | Q114867802 |
| | Discovery and resupply of pharmacologically active plant-derived natural products: A review | Q22252341 |
| | The value of plants used in traditional medicine for drug discovery | Q24536929 |
| | Aristolochic acid-associated urothelial cancer in Taiwan | Q24616582 |
| | Harnessing Nature's wisdom. Turning to Nature for inspiration and avoiding her follies | Q24654279 |
| | Marine-Derived Pharmaceuticals - Challenges and Opportunities | Q28075572 |
| | Drugs from the deep: marine natural products as drug candidates | Q28181444 |
| | The evolving role of natural products in drug discovery | Q28236671 |
| | Total synthesis of taxol | Q28237249 |
| | Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum | Q28260841 |
| | Evaluation of 14 organic solvents and carriers for screening applications in zebrafish embryos and larvae | Q28484458 |
| | Modern natural products drug discovery and its relevance to biodiversity conservation | Q29353836 |
| | Can the pharmaceutical industry reduce attrition rates? | Q29616077 |
| | Natural products as sources of new drugs over the 30 years from 1981 to 2010 | Q29616640 |
| | Ethnopharmacology in the 21st century - grand challenges | Q30396111 |
| | Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration | Q30498042 |
| | Natural products and combinatorial chemistry: back to the future | Q30832368 |
| | Drug discovery and natural products: end of an era or an endless frontier? | Q30866998 |
| | Natural Products in High Throughput Screening: Automated High-Quality Sample Preparation | Q30875177 |
| | The UIC ICBG (University of Illinois at Chicago International Cooperative Biodiversity Group) Memorandum of Agreement: a model of benefit-sharing arrangement in natural products drug discovery and development | Q33198679 |
| | Marcel Faber Roundtable: is our antibiotic pipeline unproductive because of starvation, constipation or lack of inspiration? | Q33231839 |
| | A high-throughput cell-based assay for inhibitors of ABCG2 activity | Q33234390 |
| | Strategies for efficient lead structure discovery from natural products. | Q33247330 |
| | Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective | Q33536938 |
| | Automated high-throughput system to fractionate plant natural products for drug discovery | Q33541158 |
| | Chip-based high-throughput screening of herbal medicines | Q33706575 |
| | What every chemist should know about plant names | Q33740620 |
| | Natural products as catalysts for innovation: a pharmaceutical industry perspective | Q33935913 |
| | Natural product-like synthetic libraries | Q33935923 |
| | Natural product libraries to accelerate the high-throughput discovery of therapeutic leads | Q34086801 |
| | The odyssey of marine pharmaceuticals: a current pipeline perspective. | Q34108147 |
| | Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry | Q34172646 |
| | The Beginnings of Drug Therapy: Ancient Mesopotamian Medicine | Q34188553 |
| | Natural products: an evolving role in future drug discovery. | Q34213315 |
| | Ethnopharmacology in drug discovery: an analysis of its role and potential contribution | Q34243907 |
| | Inverse Virtual Screening allows the discovery of the biological activity of natural compounds. | Q34248586 |
| | Diagnosing the decline in pharmaceutical R&D efficiency | Q34257771 |
| | A natural history of botanical therapeutics | Q34308434 |
| | Natural products: a continuing source of novel drug leads | Q34328933 |
| | Pharmaceutically relevant metabolites from lichens | Q34333797 |
| | Marine antitumor drugs: status, shortfalls and strategies. | Q34356560 |
| | A historical overview of natural products in drug discovery. | Q34426191 |
| | Marine actinobacteria as a drug treasure house | Q38775907 |
| | Natural product extracts of the Canadian prairie plant, Thermopsis rhombifolia, have anti-cancer activity in phenotypic cell-based assays | Q38937875 |
| | Antifungal potential of marine natural products. | Q39034317 |
| | Secondary Metabolites from the Marine Sponge Genus Phyllospongia | Q39076820 |
| | Deep Sea Actinomycetes and Their Secondary Metabolites | Q39308535 |
| | Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations | Q39550489 |
| | From the plant to chemistry--the early history of "rheumatic medication" | Q40420842 |
| | The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents | Q40619566 |
| | Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products | Q44015907 |
| | Chemistry. The renaissance of natural products as drug candidates | Q46766095 |
| | Penicillium commune metabolic profile as a promising source of antipathogenic natural products | Q46773719 |
| | Acetylcholinesterase inhibitory activity of pyrrolizidine alkaloids from Echium confusum Coincy | Q46981303 |
| | Ethnopharmacology and drug discovery | Q47262613 |
| | Anticoagulant activity of a natural protein purified from Hypomesus olidus. | Q51190837 |
| | Biodiversity law could stymie research. | Q51638451 |
| | Systems biology and combination therapy in the quest for clinical efficacy. | Q51934858 |
| | Chemical composition, cytotoxicity, antimicrobial and antifungal activity of several essential oils. | Q53830165 |
| | Medicinal Natural Products | Q56502446 |
| | Good Practices: The basis for evidence-based medicines | Q57057905 |
| | Antioxidant and antibacterial activities and polyphenolic constituents of Helianthemum sessiliflorum Pers | Q58855967 |
| | Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity | Q34563795 |
| | Toward personalized nutrition: comprehensive phytoprofiling and metabotyping. | Q34591656 |
| | Plant natural products: back to the future or into extinction? | Q34638367 |
| | New therapies from old medicines | Q34850059 |
| | Synergy research: approaching a new generation of phytopharmaceuticals | Q34943025 |
| | Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents | Q35100558 |
| | Emerging R and D law: the Nagoya Protocol and its implications for researchers | Q35125929 |
| | Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting | Q35149474 |
| | The relevance of higher plants in lead compound discovery programs. | Q35172533 |
| | Metal impurities cause false positives in high-throughput screening campaigns | Q35181932 |
| | Lessons from natural molecules | Q35986033 |
| | The role of natural product chemistry in drug discovery | Q35994110 |
| | Bringing medicinal plants into cultivation: opportunities and challenges for biotechnology. | Q36076135 |
| | Ethnopharmacology and systems biology: a perfect holistic match | Q36199280 |
| | Molecular understanding and modern application of traditional medicines: triumphs and trials. | Q36828585 |
| | Evolution and current status of the phytochemistry of nitrogenous compounds | Q36919168 |
| | The value of natural products to future pharmaceutical discovery | Q37011457 |
| | Matching the power of high throughput screening to the chemical diversity of natural products | Q37240957 |
| | Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. | Q37400626 |
| | Quality control of herbal material and phytopharmaceuticals with MS and NMR based metabolic fingerprinting | Q37415523 |
| | GAP Production of TCM Herbs in China | Q37809496 |
| | Sustainable medicines and global health care | Q37838824 |
| | Probing the links between in vitro potency, ADMET and physicochemical parameters. | Q37848051 |
| | Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures | Q37853908 |
| | How to cope with the quest for new antibiotics. | Q37868070 |
| | Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. | Q37985230 |
| | Nutraceuticals and botanicals: overview and perspectives | Q37987553 |
| | Extraction of plant secondary metabolites. | Q37988441 |
| | Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery | Q38028561 |
| | Chemical ecology of endophytic fungi: origins of secondary metabolites | Q38030129 |
| | Natural product isolation--how to get from biological material to pure compounds | Q38080416 |
| | Medicinal plants with anti-inflammatory activities | Q38556732 |
| | Natural products from Cuscuta reflexa Roxb. with antiproliferation activities in HCT116 colorectal cell lines. | Q38756238 |
| | Quinone/hydroquinone meroterpenoids with antitubercular and cytotoxic activities produced by the sponge-derived fungus Gliomastix sp. ZSDS1-F7. | Q38758126 |
| | Phenolic compounds from Glycyrrhiza pallidiflora Maxim. and their cytotoxic activity | Q38769326 |
| P433 | issue | 16 | |
| P921 | main subject | natural product | Q901227 |
| | drug discovery | Q1418791 |
| P304 | page(s) | 1926-1950 | |
| P577 | publication date | 2017-07-27 | |
| P1433 | published in | Natural Product Research | Q6980583 |
| P1476 | title | Natural products for human health: an historical overview of the drug discovery approaches | |
| P478 | volume | 32 | |